Stock Events

Stock Events

Dogwood Therapeutics 

$2.29
53
-$0.07-2.97% 20:00 Today
+$0.06+2.62%20:20After hours

Statistics

Day High
2.37
Day Low
2.25
52W High
9.5
52W Low
1.28
Volume
69,822
Avg. Volume
80,136
Mkt Cap
77.84M
P/E Ratio
1.21
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-8.45
-5.68
-2.91
-0.14
Expected EPS
-0.155
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-35.51MNet Income

Analyst Ratings

12.00Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DWTX. It's not an investment recommendation.
NVIDIA
6
NVDA
Amazon
5
AMZN
Apple
4
AAPL
Tesla
4
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on antiviral drugs, directly competing with Virios in the antiviral space.
Merck
MRK
Mkt Cap366B
Merck & Co. develops treatments for infectious diseases, including antivirals, making it a direct competitor.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a strong portfolio in antiviral drugs, competing in the same market as Virios.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a significant presence in the antiviral drug market, making it a competitor to Virios.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops and markets antiviral medications, positioning it as a competitor to Virios.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb offers antiviral drugs, competing with Virios in the pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division, competes in the antiviral space with Virios.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in the development of antiviral treatments, making it a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals focuses on infectious diseases, including antivirals, competing with Virios.
Novartis
NVS
Mkt Cap292.35B
Novartis AG has a diverse portfolio that includes antiviral drugs, competing with Virios in the pharmaceutical market.

About

Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
Show more...
CEO
Gregory Duncan
Employees
8
Country
United States
ISIN
US92829J2033

Listings

XNAS
US
DWTX
BOATS
BOATS
DWTX.BOATS

0 Comments

Share your thoughts

FAQ

What is Dogwood Therapeutics stock price today?▼
The current price of DWTX is $2.29 USD — it has decreased by -2.97% in the past 24 hours. Watch Dogwood Therapeutics stock price performance more closely on the chart.
What is Dogwood Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Dogwood Therapeutics stocks are traded under the ticker DWTX.
Is Dogwood Therapeutics stock price growing?▼
DWTX stock has fallen by -13.58% compared to the previous week, the month change is a +27.93% rise, over the last year Dogwood Therapeutics has showed a -54.2% decrease.
What is Dogwood Therapeutics market cap?▼
Today Dogwood Therapeutics has the market capitalization of 77.84M
When is the next Dogwood Therapeutics earnings date?▼
Dogwood Therapeutics is going to release the next earnings report on November 05, 2026.
What were Dogwood Therapeutics earnings last quarter?▼
DWTX earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.14 USD resulting in a -142.86% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dogwood Therapeutics revenue for the last year?▼
Dogwood Therapeutics revenue for the last year amounts to 0 USD.
What is Dogwood Therapeutics net income for the last year?▼
DWTX net income for the last year is -35.51M USD.
How many employees does Dogwood Therapeutics have?▼
As of September 04, 2026, the company has 8 employees.
In which sector is Dogwood Therapeutics located?▼
Dogwood Therapeutics operates in the Health & Wellness sector.
When did Dogwood Therapeutics complete a stock split?▼
The last stock split for Dogwood Therapeutics was on October 09, 2024 with a ratio of 1:25.
Where is Dogwood Therapeutics headquartered?▼
Dogwood Therapeutics is headquartered in ALPHARETTA, United States.